Effect of Somatotropin of Mammalian Cell Origin in Growth Hormone Deficiency

Frasier, S. Douglas; Rudlin, C.R.; Zeisel, Hans; Liu, Hannen H.; Long, Pamela C.; Senior, Boris; Finegold, David N.; Bercu, Barry B.; Marks, James F.; Redmond, Geoffrey P.

doi:10.1001/archpedi.1992.02160170062016

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant human growth hormone (hGH) can be produced in E. coli culture or animal cells, following the procedures routinely used for the commercial production of this protein (Becker and Hsiung, 1986;Flodh, 1986;Frasier et al, 1992). However, the amounts of hGH currently produced by the pharmaceutical industry using conventional prokaryotic or eukaryotic systems remain unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Proteins from Transgenic Cows’ Milk

Bercovich¹,

Melo²,

Criscuolo³

2010

Cells and Culture

View full text Add to dashboard Cite

Bacteria, yeast and mammalian cell cultures have been used over the past decades for the production of commercially important biological molecules. However, the use of these production systems to obtain complex proteins involves high cost procedures and technically demanding processes. During the last few years, the pharmaceutical industry has focused on the production of recombinant proteins with potential therapeutic applications, in the mammary gland of transgenic animals. The reason for this is that replacing conventional bioreactors with transgenic livestock offers immense economic benefits. Here we report the high yield production of recombinant human growth hormone (hGH) in the milk of cloned transgenic cows, and the successful obtaining of a bovine rodeo which is transgenic for the production of different proteins of high pharmaceutical and economical interest, such as human insulin and bovine growth hormone (bGH).

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Proteins from Transgenic Cows’ Milk

Bercovich¹,

Melo²,

Criscuolo³

2010

Cells and Culture

View full text Add to dashboard Cite

show abstract

Long-Term Therapy with Recombinant

Bercu

Murray

Frasier

et al. 2001

ENDO

View full text Add to dashboard Cite

In an open-label study, 69 children with organic or idiopathic growth hormone deficiency (GHD) were treated with recombinant human growth hormone (Saizen) for an average of 64.4 mo, with treatment periods as long as 140.9 mo. Auxologic measurements, including height velocity, height standard deviation score, and bone age, were made on a regular basis. The data suggest that long-term treatment with Saizen in children with GHD results in a positive catch-up growth response and proportionate changes in bone age vs height age during treatment. In addition, long-term Saizen therapy was well tolerated, with the majority of adverse events related to common childhood disorders or existing baseline medical conditions and not to study treatment. There were no significant changes in laboratory safety data or vital signs, and no positive antibody tests for Saizen.

show abstract

Outcome of Growth Hormone Therapy in Children with Growth Hormone Deficiency Showing an Inadequate Response to Growth Hormone-Releasing Hormone

Saenger

Pescovitz

Bercu

et al. 2001

ENDO

View full text Add to dashboard Cite

Saizen (recombinant growth hormone [GH]), 0.2 mg/(kg x wk), was given in an open-label fashion for an average of 51 mo to 27 children with presumed idiopathic GH deficiency who had withdrawn from a trial of Geref (recombinant GH-releasing hormone [GHRH] 1-29) because of inadequate height velocity (HV) (25 children), the onset of puberty (1 child), or injection site reactions (1 child). Measurements were made every 3-12 mo of a number of auxologic variables, including HV, height standard deviation score, and bone age. The children in the study showed excellent responses to Saizen. Moreover, first-year growth during Saizen therapy was inversely correlated with the GH response to provocative GHRH testing carried out 6 and 12 mo after the initiation of Geref treatment. These findings indicate that GH is effective in accelerating growth in GH-deficient children who do not show or maintain a satisfactory response to treatment with GHRH. In addition, they suggest that the initial response to GH therapy used in this way can be predicted by means of provoc-ative testing.

show abstract

Effect of Somatotropin of Mammalian Cell Origin in Growth Hormone Deficiency

Cited by 4 publications

References 35 publications

Therapeutic Proteins from Transgenic Cows’ Milk

Therapeutic Proteins from Transgenic Cows’ Milk

Long-Term Therapy with Recombinant

Outcome of Growth Hormone Therapy in Children with Growth Hormone Deficiency Showing an Inadequate Response to Growth Hormone-Releasing Hormone

Contact Info

Product

Resources

About